Impressive efficacy but worrisome bleeding was seen for a new type of blood clot preventer tested by Merck & Co in one of the largest heart-drug studies ever conducted, researchers said on Saturday, raising questions whether the company will seek approval of the drug and whether it can pass muster with regulators.
- Regeneron climbs after raising Eylea sales outlook
- Prenatal drug targeted lesbians, researchers say
- Man dies feet from ER after hospital says to call 911
- Abbott shares rise after analyst rates as “Buy”
- J&J again seeks more approvals for clot blocker